Safety considerations with mycophenolate sodium

Expert Opinion on Drug Safety

Volumn 6, Issue 4, 2007, Pages 445-449

  Filler, Guido ^a   Buffo, Ilan ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Drug drug interaction; Metabolism; Mycophenolate mofetil; Mycophenolate sodium; Pharmacokinetics

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; DRUG DERIVATIVE; PRODRUG;

AREA UNDER THE CURVE; BIOEQUIVALENCE; CARDIAC GRAFT REJECTION; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; ENTERIC COATED TABLET; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY GRAFT REJECTION; LEUKOCYTE COUNT; LEUKOPENIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; ORGAN TRANSPLANTATION; REVIEW; SIDE EFFECT; VOMITING; ANIMAL;

ANIMALS; HUMANS; MYCOPHENOLIC ACID; PRODRUGS; TABLETS, ENTERIC-COATED;

EID: 34548474071     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.6.4.445     Document Type: Review

References (37)

1. TAKEMOTO SK: Maintenance immunosuppression. Clin. Transpl. (2001):223-236.
2. NOWAK I, WU J, BRAYMAN KL, SHAW LM: Is the glucuronide metabolite of MPA pharmacologically active? Transplant. Proc. (1997) 29(1-2):337.
3. ALLISON AC, EUGUI EM: Mycophenolate mofetil and its mechanisms of action. Immunopharmacology (2000) 47(2-3):85-118.
4. COHN RG, MIRKOVICH A, DUNLAP B et al.: Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation (1999) 68(3):411-418.
5. EUGUI EM, MIRKOVICH A, ALLISON AC: Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scan. J. Immunol. (1991) 33(2):175-183.
6. SRINIVAS TR, KAPLAN B, MEIER-KRIESCHE HU: Mycophenolate mofetil in solid-organ transplantation. Expert Opin. Pharmacother. (2003) 4(12):2325-2345.
7. DANOVITCH GM: Mycophenolate mofetil: a decade of clinical experiencee. Transplantation (2005) 80(Suppl. 2):S272-S273.
8. PELLETIER RP,, AKIN B, HENRY ML et al.: The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin. Transplant. (2003) 17(3):200-205.
9. SRINIVAS TR, KAPLAN B, MEIER-KRIESCHE HU: Mycophenolate mofetil in solid-organ transplantation. Expert Opin. Pharmacother. (2003) 4(12):2325-2345.
10. KNOLL GA, MACDONALD I, KHAN A et al.: Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J. Am. Soc. Nephrol. (2003) 14(9):2381-2386.
11. BEHREND M, BRAUN F: Enteric-coated mycophenolate sodium: tolerability profile compared with mycophenolate mofetil. Drugs (2005) 65(8):1037-1050.
12. BUDDE K, GLANDER P, DIEKMANN F et al.: Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin. Pharmacother. (2004) 5(6):1333-1345.
13. GABARDI S, TRAN JL, CLARKSON MR: Enteric-coated mycophenolate sodium. Ann. Pharmacother. (2003) 37(11):1685-1693.
14. ARNS W, BREUER S, CHOUDHURY S et al.: Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin. Transplant. (2005) 19(2):199-206.
15. SALVADORI M, HOLZER H, DE MATTOS A et al.: Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am. J. Transplant. (2004) 4(2):231-236.
16. SOLLINGER H: Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients. Transplant. Proc. (2004) 36(Suppl. 2):S517-S520.
17. HESSELINK DA, VAN HEST RM, MATHOT RA et al.: Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am. J. Transplant. (2005) 5:987-994.
18. FILLER G, LATHIA A, LEBLANC C, CHRISTIANS U: Unexpectedly high exposure to enteric-coated mycophenolate sodium upon once-daily dosing. Pediatr. Nephrol. (2006) 21(8):1206-1208.
19. BUDDE K, GLANDER P, KRAMER BK et al.: Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. Transplantation (2007) 83(4):417-424.
20. KOBASHIGAWA JA, RENLUND DG, GEROSA G et al.: Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J. Heart Lung Transplant. (2006) 25(8):935-941.
21. BUDDE K, GLANDER P, DIEKMANN F et al.: Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients. Transplant. Proc. (2004) 36(Suppl. 2):S524-S527.
22. BUDDE K, CURTIS J, KNOLL G et al.; ERL B302 STUDY GROUP: Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am. J. Transplant. (2004) 4(2):237-243.
23. PIETRUCK F, BUDDE K, SALVADORI M et al.: Efficacy and safety of enteric-coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analysis from three clinical trials. Clin. Transplant. (2007) 21(1):117-125.
24. VAN GELDER T, LE MEUR Y, SHAW LM et al.: Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther. Drug Monit. (2006) 28(2):145-154.
25. CATTANEO D, PERICO N, GASPARI F, GOTTI E, REMUZZI G: Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. (2002) 62(3):1060-1067.
26. FILLER G: Value of therapeutic drug monitoring of MMF therapy in pediatric transplantation. Pediatr. Transplant. (2006) 10(6):707-711.
27. VOGT B, ANTONIADIS A, KLINGER M, VITKO S: Efficacy and safety of enteric-coated mycophenolate sodium (myfortic) in de novo renal transplant recipients: results of a 12-month multicenter, open-label, prospective study. Transplant. Proc. (2006) 38(5):1301-1306.
28. BEHREND M, BRAUN F: Enteric-coated mycophenolate sodium: tolerability profile compared with mycophenolate mofetil. Drugs (2005) 65(8):1037-1050.
29. TEDESCO-SILVA H, BASTIEN MC, CHOI L et al.: Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil. Transplant. Proc. (2005) 37(2):852-855.
30. ETTENGER R, BARTOSH S, CHOI L et al.: Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. Pediatr. Transplant. (2005) 9(6):780-787.
31. MASSARI P, DURO-GARCIA V, GIRON F et al.: Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients. Transplant. Proc. (2005) 37(2):916-919.
32. KAPLAN B, MEIER-KRIESCHE HU, MINNICK P et al.: Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. Clin. Transplant. (2005) 19(4):551-558.
33. FILLER G, ZIMMERING M, MAI I: Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr. Nephrol. (2000) 14(2):100-104.
34. CHRISTIANS U, STROM T, ZHANG YL et al.: Active drug transport of immunosuppressants. New insights for pharmacokinetics and pharmacodynamics. Ther. Drug Monit. (2006) 28(1):39-44.
35. CATTANEO D, MERLINI S, BALDELLI S et al.: Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients. Ther. Drug Monit. (2006) 28(5):643-649.
36. VAN HEST RM, MATHOT RA, PESCOVITZ MD, GORDON R, MAMELOK RD, VAN GELDER T: Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J. Am. Soc. Nephrol. (2006) 17(3):871-880.
37. VAN GELDER T, SHAW LM: The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation (2005) 80(Suppl. 2):S244-S253.